VALLEY COTTAGE, N.Y., Sept. 16, 2016 /PRNewswire/ -- The Center for the Biology of Chronic Disease (CBCD) announces the publication of a new paper that reports the results of a clinical study that tested the natural Gene-Eden-VIR/Novirin in genital herpes. The study showed that treatment with Gene Eden-VIR/Novirin safely and effectively decreases the number of genital herpes outbreaks. The study also showed that Gene-Eden-VIR/Novirin is more effective and safer than the leading drugs Acyclovir, Valacyclovir, and Famciclovir. These drugs are considered the best drugs available against viruses, and are widely used as the first-line treatment in viral infections. Surprisingly, the study showed that the natural Gene-Eden-VIR/Novirin is better than these drugs.
The study was published in the important medical journal Drug Design, Development and Therapy (1). The following are links to the study, and a movie where Dr. Hanan Polansky and Dr. Edan Itzkovitz talk about the study.
According to Dr. Hanan Polansky, "To the best of our knowledge, this is the first time that a dietary supplement was shown to be more effective than the leading drugs in an important drug category."
Gene-Eden-VIR/Novirin is a patented botanical product that consists of five natural ingredients, quercetin, green tea extract, cinnamon extract, licorice extract, and selenium. The product was developed to target latent viruses. Gene-Eden-VIR/Novirin was introduced in the marketplace at the end of 2009. A previous clinical study showed that Gene-Eden-VIR/Novirin is antiviral (2).
The scientists, who developed the Gene-Eden-VIR/Novirin formula, used a unique scientific tool, Computer Intuition, a proprietary psycholinguistic-based, data-mining program that analyzes scientific text. The scientists' objective was to identify natural ingredients found in the scientific literature that have a strong antiviral effect against the most common viruses. To achieve the objective, the scientists used the computer program to analyze more than 50,000 papers. The results assisted the scientists in selecting the best ingredients and the most effective dosages. (2)
The study compared the clinical effects of suppressive treatment with Gene-Eden-VIR/Novirin with those reported in published clinical studies that tested Acyclovir, Valacyclovir, and Famciclovir, the three leading drugs approved by the FDA for the treatment of genital herpes. The clinical effects were "time to first recurrence," "% of participants with 50% reduction in the number of outbreaks," "mean monthly recurrence," "% of participants who were recurrence-free," "mean % reduction in recurrence," and "% of participants with decrease in recurrences." Out of the 15 tests that compared Gene-Eden-VIR/Novirin to the three drugs, Gene-Eden-VIR/Novirin had superior efficacy in eight tests, inferior efficacy in three tests, and comparable efficacy in four tests. Gene-Eden-VIR/Novirin also had superior safety.
In summary, this study showed that suppressive treatment with Gene-Eden-VIR/Novirin safely decreased the number of genital herpes outbreaks. The study also showed that the clinical effects of Gene-Eden-VIR/Novirin are mostly better than those of Acyclovir, Valacyclovir, and Famciclovir.
About the CBCD
The Center for the Biology of Chronic Disease (CBCD) (http://www.cbcd.net) is a not-for-profit research organization. The CBCD's mission is to advance the research on the effect of foreign DNA on the public's health, and on treatments for the diseases caused by foreign DNA.
- Polansky, H. Javaherian, A. Itzkovitz E. Clinical study in genital herpes: natural Gene-Eden-VIR/Novirin versus acyclovir, valacyclovir, and Famciclovir. Drug Design, Development and Therapy 2016:10 2713-2722
- Polansky H, Itzkovitz E. Gene-Eden-VIR is antiviral: results of a post marketing clinical study. Pharmacol Pharm. 2013;4(6A):1-8
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/antiviral-dietary-supplement-more-effective-than-acyclovir-valacyclovir-and-famciclovir-cbcd-reports-publication-of-a-new-clinical-study-300329017.html
SOURCE The Center for the Biology of Chronic Disease